Pancreatic Cancer Research

ResearcherUniversity of TsukubaActive in the last 2 years

Hiroaki Tateno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3006-1659; OpenAlex author ID A5080209601. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 12

  1. GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. Last author DOI 10.1002/advs.202514735↗
  2. Targeting Interactions Between Siglec-10 and α3β1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0977↗
  3. Identification of CLEC10A as a human lectin for pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-025-02404-1↗
  4. Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. Last author DOI 10.1155/2024/1529449↗
  5. Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer. Last author DOI 10.1002/ijc.34362↗
  6. rBC2LCN-reactive SERPINA3 is a glycobiomarker candidate for pancreatic ductal adenocarcinoma. Last author DOI 10.1093/glycob/cwad009↗
  7. Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN lectin. Co-author DOI 10.1111/cas.15846↗
  8. CD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12876-022-02228-7↗
  9. Quantitative structural analysis of glycans expressed within tumors derived from pancreatic cancer patient-derived xenograft mouse models. Last author DOI 10.1016/j.bbrc.2020.11.087↗
  10. Carcinoembryonic antigen as a specific glycoprotein ligand of rBC2LCN lectin on pancreatic ductal adenocarcinoma cells. Last author DOI 10.1111/cas.15023↗
  11. Novel Pancreatic Cancer Therapy Targeting Cell Surface Glycans by Liposomes Modified with rBC2LCN Lectin. Last author DOI 10.1159/000513430↗
  12. A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin-Drug Conjugate (LDC). Co-author DOI 10.1158/1535-7163.mct-17-0232↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatsuya Oda · 10 shared papers, 2018–2026 · strength 1.77
  2. Osamu Shimomura · 10 shared papers, 2018–2026 · strength 1.77
  3. Yoshihiro Miyazaki · 5 shared papers, 2020–2025 · strength 0.83
  4. Tomoaki Furuta · 5 shared papers, 2020–2024 · strength 0.75
  5. Yukihito Kuroda · 4 shared papers, 2020–2024 · strength 0.67
  6. Hiromitsu Nakahashi · 3 shared papers, 2023–2025 · strength 0.61
  7. Yoshimasa Akashi · 3 shared papers, 2021–2024 · strength 0.48
  8. Tsuyoshi Enomoto · 2 shared papers, 2020–2025 · strength 0.35
  9. Sota Kimura · 3 shared papers, 2018–2021 · strength 0.30
  10. Koichiro Kumano · 1 shared paper, 2026 · strength 0.30
  11. Dinh Xuan Tuan Anh · 1 shared paper, 2026 · strength 0.30
  12. Rahul Suresh Shinde · 1 shared paper, 2026 · strength 0.25
  13. Gauri Mirji · 1 shared paper, 2026 · strength 0.25
  14. Pratima Saini · 1 shared paper, 2026 · strength 0.25
  15. Mohamed Abdel‐Mohsen · 1 shared paper, 2026 · strength 0.25
  16. Shuntaro Tsukamoto · 1 shared paper, 2025 · strength 0.25
  17. Kentaro Hatano · 1 shared paper, 2023 · strength 0.20
  18. Haruki Odaka · 1 shared paper, 2022 · strength 0.20
  19. Shuuji Mawaribuchi · 1 shared paper, 2023 · strength 0.19
  20. Takahito Nakajima · 1 shared paper, 2023 · strength 0.16
  21. Kayo Hasehira · 1 shared paper, 2021 · strength 0.16
  22. Nobuhiro Ohkohchi · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.